Aprea Therapeutics shares surge 10.64% intraday after APR-1051 shows partial response in trial and completes oversubscribed $30M private placement.

Aprea Therapeutics surged 10.64% intraday, driven by the confirmation of a partial response in a PPP2R1A-mutated endometrial cancer patient in the phase 1 ACESOT-1051 trial of its WEE1 inhibitor APR-1051, with a 50% tumor shrinkage and significant drop in CA-125. On the same day, the company announced the completion of an oversubscribed $30 million private placement, expected to extend its cash runway through the first quarter of 2028.